Cray/Media: Mardi Larson, 612/683-3538 Cray/Financial: Brad Allen, 612/683-7395 BRISTOL-MYERS SQUIBB ORDERS NEW CRAY SYSTEM, MOST POWERFUL IN PHARMACEUTICAL INDUSTRY EAGAN, Minn., Jan. 5, 1995 -- Bristol-Myers Squibb (BMS) has installed and accepted a four-processor CRAY C90 supercomputer system for molecular modeling and drug discovery research, Cray Research (NYSE:CYR) announced today. Cray officials said that the system, installed at BMS's Pharmaceutical Research Institute, Lawrenceville, N.J., is the largest Cray supercomputer in the pharmaceutical industry. The CRAY C90 supercomputer is an upgrade replacement of a CRAY Y-MP system BMS installed three years ago. According to Joseph J. Villafranca, Ph.D., executive director of macromolecular structure at BMS, the Cray system will be used for exploratory and drug discovery research by about 250 chemists, molecular modelers, and crystallographers located throughout four BMS research sites. BSM estimates that by using Cray Research supercomputers the company can substantially expedite the drug discovery cycle for certain programs, Dr. Villafranca said. "This translates into our ability to take molecules into the clinic faster and potentially reduce the development cycle," he said. "In addition to the value of reducing development cycles, we picked the Cray system for one clear reason -- in our three years with the CRAY Y-MP system we experienced only one down day attributed to a hardware problem," said Dr. Villafranca. "The service we receive is extremely superior as well. When we have any slight problem or need advice or help to carry out our normal periodic maintenance, the service provided by Cray engineers is instantaneous." Robert H. Ewald, Cray Research president and chief operating officer, said, "We are pleased to continue our relationship with Bristol-Myers Squibb and to see our supercomputing solutions provide a strong return on investment for our industrial customers." Cray Research provides the leading supercomputing tools and services to help solve customers' most challenging problems. ###